Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior Pharmaceuticals, Inc. Chief Accounting Officer Anderson Woodrow D reported equity award vesting and related share movements on March 3, 2026. Performance stock units granted on March 3, 2023 vested at 76.6%, resulting in 18,364 common shares out of a 23,975 target amount, and restricted stock units also vested.
To cover tax withholding tied to these vestings, 8,283 and 2,682 common shares were disposed of at $31.98 per share through tax-withholding transactions, rather than open-market sales. After these derivative conversions and tax withholdings, the reporting person held 24,638 shares of common stock directly.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported equity award activity involving performance stock units and common stock. In 2024, 204,904 shares vested from performance stock units granted on March 3, 2021 and were subject to a further two-year holding period. On March 3, 2026, this holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. On the same date, 86,949 shares of common stock vested from performance stock units granted on March 3, 2023 after performance conditions were determined to be met at 76.6% of a 113,510 share target. Each performance stock unit represents a contingent right to receive one share of common stock. After these transactions, Preblick held 317,292 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. Chief Legal Officer Jeffrey W. Burris reported the vesting of performance stock units on March 3, 2026. The units vested after performance conditions were determined to be met at 76.6%, resulting in 79,893 common shares vesting from a 104,300 target grant made on March 3, 2023. Each performance stock unit corresponded to one share of common stock. To cover tax withholding obligations from this vesting, 36,032 shares of common stock were disposed of at a price of $31.98 per share, leaving Burris with 71,518 directly owned common shares after these transactions.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder had performance stock units granted on March 3, 2023 vest on March 3, 2026 after performance conditions were determined to be met at 76.6%. This resulted in 101,544 shares of common stock vesting out of a 132,565 target amount, with each unit representing one share. To cover tax withholding related to this vesting, 45,797 shares of common stock were disposed of at $31.98 per share. Following these transactions, Heidbreder directly held 246,509 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. describes its transition to a U.S.-domiciled parent company and its core focus on treating opioid use disorder (OUD), led by long-acting injectable SUBLOCADE and sublingual SUBOXONE Film and SUBUTEX.
The company reports that the U.S. generated 85% of net revenues in 2025, driven mainly by SUBLOCADE, which delivered $856 million of 2025 global net sales versus $346 million from sublingual products. SUBLOCADE has treated more than 475,000 patients since approval and gained an FDA label expansion in 2025 enabling rapid initiation and more flexible injection sites.
Indivior highlights 2025 developments including CEO succession to Joseph Ciaffoni, inclusion in major U.S. equity indices, restructuring of R&D and Medical Affairs, and exit from several smaller Rest of World markets to concentrate on the U.S., Canada, Australia, France, and Germany. The company also outlines a pipeline featuring INDV-6001, a potential three‑month buprenorphine injection, and INDV-2000, a non‑opioid OUD candidate, both with Phase 2 studies completed in 2025 and results expected in 2026.
Indivior Pharmaceuticals, Inc. reported a strong fourth quarter and full-year 2025, driven by its long-acting opioid use disorder treatment SUBLOCADE. 2025 net revenue reached $1,239 million, up from $1,188 million, with total SUBLOCADE net revenue rising to $856 million from $756 million.
GAAP net income improved sharply to $210 million from $7 million, while non-GAAP net income increased to $320 million. Adjusted EBITDA grew to $428 million from $358 million, lifting the adjusted EBITDA margin to 35%. The company highlighted cost reductions and a simplified operating model following its U.S. domestication completed in January 2026.
For 2026, Indivior guides total net revenue of $1,125–$1,195 million and SUBLOCADE net revenue of $905–$945 million, with non-GAAP operating expenses of $430–$450 million and adjusted EBITDA of $535–$575 million. It expects about $300 million in cash flow from operations and has authorized a new $400 million share repurchase program while maintaining a low leverage ratio of 0.7x.
Indivior Pharmaceuticals, Inc. received a disclosure that a group of investment entities led by Madison Avenue International LP holds a significant minority stake in its ordinary shares. As of February 17, 2026, the group beneficially owned 6,280,502 ordinary shares.
This position represents approximately 5.0% of Indivior’s outstanding ordinary shares, based on 124,853,897 shares outstanding as of October 1, 2025. The reporting investors state that the shares were not acquired for the purpose of changing or influencing control of the company.
Indivior Pharmaceuticals, Inc. disclosed that Fuller & Thaler Asset Management, Inc., a California-based investment adviser, beneficially owns 6,371,533.70 shares of its common stock, representing 5.10% of the class as of 12/31/2025.
Fuller & Thaler reports sole voting power over 6,193,613.70 shares and sole dispositive power over 6,371,533.70 shares, with no shared voting or dispositive power. The firm states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior.
Indivior Pharmaceuticals, Inc. reported that Chief Accounting Officer Anderson Woodrow D acquired company equity through compensation awards. He received 6,903 shares of common stock at a price of $0, bringing his directly held common stock to 11,293 shares.
He was also granted 23,975 performance stock units at $0, following certification of performance conditions on February 9, 2026. These performance-based awards are scheduled to vest on March 3, 2026, subject to continued employment, while the restricted stock units vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc.’s Chief Financial Officer Ryan Preblick reported equity awards rather than open-market trades. He received a grant of 37,358 restricted stock units with a stated price of $0, increasing his directly held common stock to 317,940 shares after the award.
He was also credited with 113,510 performance stock units at an exercise price of $0. These relate to a conditional award originally granted on March 3, 2023, for 113,510 shares, with performance conditions certified on February 9, 2026. The award is scheduled to vest on March 3, 2026 and then remain subject to a further two-year holding period before the vested shares are released. The RSUs vest in three equal annual installments beginning February 10, 2027, conditioned on his continued service.